Welcure Drugs & Pharmaceuticals Ltd (WELCURE)

Loading page…

Welcure Drugs & Pharmaceuticals Ltd (WELCURE) · mywealthgrid

About

Welcure Drugs & Pharmaceuticals Ltd operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹1

Market cap

₹26 Cr

P/E

463.5×

P/B

0.3×

Dividend yield

ROE

-5.5%

ROCE

-2.1%

Debt / equity

OPM

-1.9%

EPS (TTM)

₹0.0

Book value

₹0.8

52-week high

—

52-week low

—

476 historical price candles were omitted because the exchange source has not been verified.

₹0.20%1Y

Quick read

rule-based

Pros

+Revenue CAGR of 389.6% over the last 5 years
+Almost debt-free (debt/equity 0)

Cons

−Low return on equity of -4.4% (3-yr avg)
−Expensive at 463.5× trailing earnings

Research score

Structured signal from quality, growth, valuation and momentum.

50/100

Business quality: 25
Growth: 100
Valuation: 25

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	—	—	0	0	0	0	0	0	0	25	366
COGS	—	—	0	0	0	0	0	0	0	21	322
Gross profit	—	—	—	—	—	—	—	—	—	4	43
	—	—	0	0	0	0	0	0	0	3	50
	—	—	-0	0	-0	0	0	-0	-0	1	-7
OPM %	—	—	-40%	0%	-12.5%	38.5%	27.3%	—	—	3.6%	-1.9%
Depreciation	—	—	0	0	0	0	0	0	0	0	0
Interest	—	—	0	0	0	0	0	0	0	0	0
	—	—	0	0	0	0	0	0	0	2	1
Profit before tax	0	0	-0	0	-0	0	0	0	-0	3	-5
Tax	—	—	0	0	0	0	0	0	0	1	0
Tax %	—	—	0%	—	0%	0%	0%	0%	0%	21.9%	0%
	0	0	-0	0	-0	0	0	0	-0	2	-5
PAT margin %	—	—	-40%	0%	-12.5%	46.2%	18.2%	—	—	8.8%	-1.5%
EPS (₹)	—	—	—	—	0	—	—	0.1	-0.1	0.4	-0
EPS adjusted (₹)	—	—	-0	0	-0	0	0	0	-0	0	-0
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	12	12	12	12	12	13	13	112	124
Reserves	-12	-12	-12	-12	-12	-12	-12	-10	-27
	0	0	0	0	0	0	0	123	0
	0	0	0	0	0	0	0	41	413
Total equity & liabilities	0	0	0	0	0	2	1	267	510
	0	0	0	0	0	0	0	0	0
CWIP	—	—	—	—	—	—	—	—	—
Investments	0	0	0	0	0	0	0	0	1
	0	0	0	0	0	1	1	267	509
Total assets	0	0	0	0	0	2	1	267	510

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	—	—	—	—	16.5%	11.8%
EBITDA margin %	0%	-12.5%	38.5%	27.3%	—	—	3.6%	-1.9%
EBIT margin %	0%	-12.5%	38.5%	27.3%	—	—	3.5%	-1.9%
PAT margin %	0%	-12.5%	46.2%	18.2%	—	—	8.8%	-1.5%
Working capital
Receivable days	0	0	0	0	—	—	282	213
Inventory days	0	0	0	0	—	—	2,554	162
Payable days	0	0	0	0	—	—	52	0
NWC days	0	0	0	0	—	—	2,784	376
Leverage
Current ratio	3	2	—	—	1	1	4.41	1.67
Debt to EBITDA	—	—	0	0	—	—	140	—
Debt to equity	0	0	0	0	0	0	1.2	0
Interest coverage	—	—	—	—	—	—	—	—
Asset turnover	2.67	4	1.86	1.1	0	0	0.09	0.72
Return ratios
Return on assets %	0%	-50%	85.7%	20%	6.5%	-12.4%	0.8%	-1.1%
Return on capital employed %	0%	-66.7%	125%	35.3%	12.3%	-12.6%	2.4%	-2.1%
Return on equity %	0%	-50%	85.7%	22.2%	6.6%	-12.7%	2.1%	-5.7%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Promoter	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
No. of shareholders	—	—	—	—	—	—	—	—	—	76,954	87,288	87,977

Promoter holding up 0 percentage points since Jun 2023.

486 deals · 10 Aug 2021 – 23 Apr 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
23 Apr 2026	KIFS ENTERPRISE	Bulk	BSE	Sell	69,76,552	₹0.31	₹0.22 Cr
15 Apr 2026	SHARE INDIA SECURITIES LIMITED	Bulk	BSE	Sell	1,08,52,665	₹0.35	₹0.38 Cr
15 Apr 2026	SHARE INDIA SECURITIES LIMITED	Bulk	BSE	Buy	1,08,52,665	₹0.35	₹0.38 Cr
15 Apr 2026	SATISH KUMAR GRANDHI	Bulk	BSE	Sell	82,90,001	₹0.34	₹0.28 Cr
19 Mar 2026	SHARE INDIA SECURITIES LIMITED	Bulk	BSE	Sell	66,24,510	₹0.26	₹0.17 Cr
19 Mar 2026	SHARE INDIA SECURITIES LIMITED	Bulk	BSE	Buy	59,25,781	₹0.25	₹0.15 Cr
4 Mar 2026	SAROJ KUMAR KUNDU	Bulk	BSE	Sell	81,17,233	₹0.29	₹0.24 Cr
4 Mar 2026	SHARE INDIA SECURITIES LIMITED	Bulk	BSE	Buy	73,31,244	₹0.30	₹0.22 Cr
4 Mar 2026	TRANSGLOBAL SECURITIES LTD.	Bulk	BSE	Buy	67,10,361	₹0.30	₹0.20 Cr
4 Mar 2026	TRANSGLOBAL SECURITIES LTD.	Bulk	BSE	Sell	58,66,777	₹0.30	₹0.18 Cr

1–10 of 486

1 / 49

Mr. CHINTAN DIDAWALA GANPATExecutive Director-MD
Mr. RAVI THAKORNon-Executive - Non Independent Director
Mr. YOGESHKUMAR PRAJAPATINon-Executive - Independent Director
Mrs. BHUMIKA PRADHANNon-Executive - Independent Director

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Welcure Drugs & Pharmaceuticals Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Face value ₹10 → ₹116 Oct 2025 · ex-date

1

Bonus 1:1016 Oct 2025 · ex-date

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

1 announcementsExport CSV

14 Jul 2026, 4:44 pmOthers

Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of Welcure Drugs & Pharmaceuticals Ltd Held On Today I.E. Tuesday, 14Th July, 2026.

Outcome without intimation PDF

Date	Category	Subject	Filing
14 Jul 2026, 4:44 pm	Others Outcome without intimation	Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of Welcure Drugs & Pharmaceuticals Ltd Held On Today I.E. Tuesday, 14Th July, 2026.	PDF

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	—	—	—	—	16.5%	11.8%
EBITDA margin %	0%	-12.5%	38.5%	27.3%	—	—	3.6%	-1.9%
EBIT margin %	0%	-12.5%	38.5%	27.3%	—	—	3.5%	-1.9%
PAT margin %	0%	-12.5%	46.2%	18.2%	—	—	8.8%	-1.5%
Working capital
Receivable days	0	0	0	0	—	—	282	213
Inventory days	0	0	0	0	—	—	2,554	162
Payable days	0	0	0	0	—	—	52	0
NWC days	0	0	0	0	—	—	2,784	376
Leverage
Current ratio	3	2	—	—	1	1	4.41	1.67
Debt to EBITDA	—	—	0	0	—	—	140	—
Debt to equity	0	0	0	0	0	0	1.2	0
Interest coverage	—	—	—	—	—	—	—	—
Asset turnover	2.67	4	1.86	1.1	0	0	0.09	0.72
Return ratios
Return on assets %	0%	-50%	85.7%	20%	6.5%	-12.4%	0.8%	-1.1%
Return on capital employed %	0%	-66.7%	125%	35.3%	12.3%	-12.6%	2.4%	-2.1%
Return on equity %	0%	-50%	85.7%	22.2%	6.6%	-12.7%	2.1%	-5.7%

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-0	0	-0	0	0	0	-0	-222	2
	0	—	—	—	—	1	0	-0	-1
	0	—	—	—	—	-1	-0	222	0
Net cash flow	-0	—	—	—	—	-0	0	0	0
Free cash flow	—	—	—	—	—	0	-0	-222	2
CFO / Operating profit %	—	—	—	80%	66.7%	—	—	—	—

Welcure Drugs & Pharmaceuticals Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

Stock splits1

Bonus issues1

Announcements

Ratio timeline

Not in the F&O segment

No fund holdings on record

Stock splits1

Bonus issues1

Announcements

Annual reports

Quarterly record

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Return on equity

1

1

1

1